KIF5B

Across TCGA pan-cancer cohorts, KIF5B Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated KIF5B data layer compared with 25 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher KIF5B Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated KIF5B expression acts as an unfavorable survival marker, although some lineages such as UCEC and BLCA show a favorable association.

LUSC, ESCA, and UCEC are the cancer types where KIF5B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	OS	Median	III,IV	0.084	0.691	<.001	33	view →
ESCA	OS	Median	III,IV	0.108	0.574	<.001	21	view →
UCEC	OS	Median	II,III,IV	0.941	0.316	.007	18	view →
COAD	DFS	Median	III,IV	0.130	0.616	.006	7	view →
SARC	DFS	Median	All	0.006	0.611	<.001	6	view →
BLCA	DFS	Median	III,IV	1.000	0.273	.044	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

KIF5B–LUSC (OS)

Open the LUSC breakdown →